Pharmacopeia gets Bristol exec
Executive Summary
Rene Belder, who led Bristol-Myers Squibb's regulatory team for the PPAR agonist Pargluva (muraglitazar), joins Pharmacopeia as VP-clinical and regulatory affairs, the Princeton, N.J. biotech announces Nov. 6. Bristol halted development of Pargluva in May, seven months after an FDA "approvable" letter for the diabetes agent suggested additional clinical trials would be necessary (1"The Pink Sheet" Dec. 19, 2005, p. 11). At Pharmacopeia, Belder will be responsible for overseeing the firm's current and future clinical development product portfolio...